SURVYR

MDT

Medtronic plc
$94.78
+$0.83 (0.88%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-20%-11%-2%+7%+17%Oct 2025Oct 2026Apr 202652w high $106.3352w low $73.31
MDTSPY
Wall St. Highest PT $121.00 (+27.7%) Wall St. Avg PT $104.62 (+10.4%)
$72$86$99$112$126POC $95Hi $121Avg $105
Underwater Drawdown %Max DD -28.9%Current -7.1%
0.0%-28.9%
Relative Strength vs SPY-9.9% vs SPYUnderperforming
+37%0%-37%
1W
+$1.34 (1.43%)
1M
+$5.28 (5.90%)
3M
+$7.95 (9.16%)
6M
+$16.76 (21.48%)
YTD
+$1.12 (1.19%)
1Y
+$4.54 (5.03%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
26 analysts · mean score 1.77
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$94.78
Average target$104.62
+$9.84 (+10.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$85.00
Median$104.62
High$121.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-12 · BTIG reiterated Buy on MDT
Initiated
2026-10-07 · Barclays started covering MDT at Equal-Weight
Reiterated
2026-09-30 · TD Cowen reiterated Buy on MDT
Reiterated
2026-09-03 · UBS reiterated Buy on MDT
Reiterated
2026-09-02 · Truist Securities reiterated Hold on MDT
Reiterated
2026-09-02 · Wells Fargo reiterated Overweight on MDT
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$122.0B
P/E (last 12 months)23.4
P/E (next 12 months, estimated)14.9
52-week range$73.31 – $106.33
Revenue growth (latest quarter vs a year ago)+13.7%
Dividend yield3.02%
Analyst consensusBuy (26)
Average analyst price target$104.62 (+10%)

What they do

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
29th percentile in sector
D+
12-1 return: -1.7%
Percentile within its GICS sector across the S&P 1500.
Growth
71st percentile in sector
B
Revenue growth (YoY): +13.7%
Percentile within its GICS sector across the S&P 1500.
Value
65th percentile in sector
B
Forward E/P: 6.8% · EBITDA/EV: 7.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
60th percentile in sector
B-
Profit margin: +13.9% · Return on equity: +10.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 352 of 499 · 12-month momentum -2.5%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MDT earningsNext report in 19 days
Next report
Tue Nov 17, 2026Before the open
EPS consensus$1.33 range $1.32–$1.34
Revenue consensus$9.5B 24 analysts
Last 4 quarters · EPS vs estimate
Sep 1, 2026$1.45est $1.39+4.5%Above estimates
Jun 3, 2026$1.55est $1.54+0.6%In line with estimates
Feb 17, 2026$1.36est $1.34+1.9%Above estimates
Nov 18, 2025$1.36est $1.31+3.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 11:07:13 ET
24-1125-0225-0525-0825-1126-0226-0626-090.001.62
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-07-31$9.8B+13.7%
2026-04-30$9.8B–
2026-01-31$9.0B–
2025-10-31$9.0B–
2025-07-31$8.6B–

Recent dividends

2026-09-25: $0.720 · 2026-06-26: $0.720 · 2026-03-27: $0.710 · 2025-12-26: $0.710 · 2025-09-26: $0.710 · 2025-06-27: $0.710 · 2025-03-28: $0.700 · 2024-12-27: $0.700

News & catalysts

More news
What Would A Short Seller Say About Stryker?
Trefis · 22h ago
Can Boston Scientific Stock Bounce Off This Support Again?
Trefis · Oct 21
IHI, MDT, RMD, BDX: Large Outflows Detected at ETF
Nasdaq · Oct 21
Rating changes
Reiterated
2026-10-12 · BTIG reiterated Buy on MDT
Initiated
2026-10-07 · Barclays started covering MDT at Equal-Weight
Reiterated
2026-09-30 · TD Cowen reiterated Buy on MDT
Reiterated
2026-09-03 · UBS reiterated Buy on MDT
Reiterated
2026-09-02 · Truist Securities reiterated Hold on MDT
Reiterated
2026-09-02 · Wells Fargo reiterated Overweight on MDT

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Martha Geoffrey
Director, Chairman and CEO · 2026-10-15
Sell
$4.8M
Marinaro Michael
EVP, Pres MedSurg and Americas · 2026-10-15
Sell
$1.0M
Kiil Harry Skip
EVP & President Cardiovascular · 2026-09-16
Sell
$138.9K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-24 11:07:13 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026